



January 29, 2026

The General Manager

Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi

Subject: Material Information

Dear Sir,

Under Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the Rule Book of Pakistan Stock Exchange Limited.

Macter International Limited (“the Company”) is pleased to inform that the Company has successfully launched **TirzaTrim (Tirzepatide) in a multidose pre-filled pen (PFP) presentation.**

Tirzepatide is a **dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist**, indicated for the management of **Type 2 Diabetes Mellitus**, with additional benefits in **glycemic control and weight reduction**. It represents a next-generation incretin-based therapy with significant clinical relevance in cardio-metabolic care.

The launch of **TirzaTrim Multidose Pre-Filled Pen** marks an important milestone in the Company's biotechnology portfolio and further strengthens Macter's position in **advanced injectable drug delivery systems** and **complex biologics** within Pakistan.

This development reflects the Company's continued commitment to introducing innovative, patient-centric therapies and expanding access to globally benchmarked treatments in the local market.

Yours truly,
For and on behalf of
Macter International Limited



Asif Javed
Company Secretary

CC: Director/HOD
Supervision Division
Securities & Exchange Commission of Pakistan
NIC Building, 63 Jinnah Avenue, Blue Area,
Islamabad